Cargando…
The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI‐derived and clinical features, predict adult primary glioblastoma survival
PURPOSE: This study aimed to integrate the TERT promoter mutation status, MGMT promoter methylation status, MRI‐derived features, and clinical features into a survival analysis model to better understand adult primary glioblastoma prognosis‐related markers. METHOD: A total of 304 adult glioblastoma...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089138/ https://www.ncbi.nlm.nih.gov/pubmed/29984907 http://dx.doi.org/10.1002/cam4.1666 |
_version_ | 1783346971609661440 |
---|---|
author | Shu, Chang Wang, Qiong Yan, Xiaoling Wang, Jinhuan |
author_facet | Shu, Chang Wang, Qiong Yan, Xiaoling Wang, Jinhuan |
author_sort | Shu, Chang |
collection | PubMed |
description | PURPOSE: This study aimed to integrate the TERT promoter mutation status, MGMT promoter methylation status, MRI‐derived features, and clinical features into a survival analysis model to better understand adult primary glioblastoma prognosis‐related markers. METHOD: A total of 304 adult glioblastoma samples collected after surgical resection were selected for retrospective analysis, and Sanger sequencing was performed to detect IDH and TERT promoter mutations. The methylation of the MGMT promoter was analyzed by pyrosequencing, and MRI‐derived and clinical features were dichotomized into easily acquired variables. Random survival forest analysis, Kaplan‐Meier analysis, Cox proportional hazard regression, and LASSO regression were performed for the survival analysis, and ROC analysis and Pearson's chi‐squared test were employed for the correlation analysis. RESULTS: Wild‐type IDH was present in 89.8% of the adult glioblastoma samples, and TERT promoter mutations and MGMT promoter methylation were observed in 66.42% and 38.49% of all adult primary glioblastomas, respectively. Age and MGMT promoter methylation were identified as independent prognostic biomarkers, and the TERT promoter mutation status and MGMT promoter methylation status, when combined with other tumor‐related factors, generated several different survival subgroups. None of the factors investigated in this study predicted the MGMT promoter status, and MRI‐detected necrosis was positively associated with TERT promoter mutations. CONCLUSION: MGMT promoter methylation and TERT promoter mutations, combined with MRI‐derived and clinical features, revealed different survival subgroups with distinct responses to current treatments, and this information increases the ability to predict the survival of adult primary glioblastoma patients. MRI‐detected necrosis often indicates the presence of TERT promoter mutations. |
format | Online Article Text |
id | pubmed-6089138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60891382018-08-17 The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI‐derived and clinical features, predict adult primary glioblastoma survival Shu, Chang Wang, Qiong Yan, Xiaoling Wang, Jinhuan Cancer Med Clinical Cancer Research PURPOSE: This study aimed to integrate the TERT promoter mutation status, MGMT promoter methylation status, MRI‐derived features, and clinical features into a survival analysis model to better understand adult primary glioblastoma prognosis‐related markers. METHOD: A total of 304 adult glioblastoma samples collected after surgical resection were selected for retrospective analysis, and Sanger sequencing was performed to detect IDH and TERT promoter mutations. The methylation of the MGMT promoter was analyzed by pyrosequencing, and MRI‐derived and clinical features were dichotomized into easily acquired variables. Random survival forest analysis, Kaplan‐Meier analysis, Cox proportional hazard regression, and LASSO regression were performed for the survival analysis, and ROC analysis and Pearson's chi‐squared test were employed for the correlation analysis. RESULTS: Wild‐type IDH was present in 89.8% of the adult glioblastoma samples, and TERT promoter mutations and MGMT promoter methylation were observed in 66.42% and 38.49% of all adult primary glioblastomas, respectively. Age and MGMT promoter methylation were identified as independent prognostic biomarkers, and the TERT promoter mutation status and MGMT promoter methylation status, when combined with other tumor‐related factors, generated several different survival subgroups. None of the factors investigated in this study predicted the MGMT promoter status, and MRI‐detected necrosis was positively associated with TERT promoter mutations. CONCLUSION: MGMT promoter methylation and TERT promoter mutations, combined with MRI‐derived and clinical features, revealed different survival subgroups with distinct responses to current treatments, and this information increases the ability to predict the survival of adult primary glioblastoma patients. MRI‐detected necrosis often indicates the presence of TERT promoter mutations. John Wiley and Sons Inc. 2018-07-09 /pmc/articles/PMC6089138/ /pubmed/29984907 http://dx.doi.org/10.1002/cam4.1666 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Shu, Chang Wang, Qiong Yan, Xiaoling Wang, Jinhuan The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI‐derived and clinical features, predict adult primary glioblastoma survival |
title | The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI‐derived and clinical features, predict adult primary glioblastoma survival |
title_full | The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI‐derived and clinical features, predict adult primary glioblastoma survival |
title_fullStr | The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI‐derived and clinical features, predict adult primary glioblastoma survival |
title_full_unstemmed | The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI‐derived and clinical features, predict adult primary glioblastoma survival |
title_short | The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI‐derived and clinical features, predict adult primary glioblastoma survival |
title_sort | tert promoter mutation status and mgmt promoter methylation status, combined with dichotomized mri‐derived and clinical features, predict adult primary glioblastoma survival |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089138/ https://www.ncbi.nlm.nih.gov/pubmed/29984907 http://dx.doi.org/10.1002/cam4.1666 |
work_keys_str_mv | AT shuchang thetertpromotermutationstatusandmgmtpromotermethylationstatuscombinedwithdichotomizedmriderivedandclinicalfeaturespredictadultprimaryglioblastomasurvival AT wangqiong thetertpromotermutationstatusandmgmtpromotermethylationstatuscombinedwithdichotomizedmriderivedandclinicalfeaturespredictadultprimaryglioblastomasurvival AT yanxiaoling thetertpromotermutationstatusandmgmtpromotermethylationstatuscombinedwithdichotomizedmriderivedandclinicalfeaturespredictadultprimaryglioblastomasurvival AT wangjinhuan thetertpromotermutationstatusandmgmtpromotermethylationstatuscombinedwithdichotomizedmriderivedandclinicalfeaturespredictadultprimaryglioblastomasurvival AT shuchang tertpromotermutationstatusandmgmtpromotermethylationstatuscombinedwithdichotomizedmriderivedandclinicalfeaturespredictadultprimaryglioblastomasurvival AT wangqiong tertpromotermutationstatusandmgmtpromotermethylationstatuscombinedwithdichotomizedmriderivedandclinicalfeaturespredictadultprimaryglioblastomasurvival AT yanxiaoling tertpromotermutationstatusandmgmtpromotermethylationstatuscombinedwithdichotomizedmriderivedandclinicalfeaturespredictadultprimaryglioblastomasurvival AT wangjinhuan tertpromotermutationstatusandmgmtpromotermethylationstatuscombinedwithdichotomizedmriderivedandclinicalfeaturespredictadultprimaryglioblastomasurvival |